Randomized, placebo-controlled trial of lisofylline for early treatment of acute lung injury and acute respiratory distress syndrome

Autor: David A. Schoenfeld, Marion Gray Secundy, Thomas M. Hyera, M. A. Matthay, Robert H. Bartlett, John M. Luce, Roger G. Spragg, Kenneth P. Steinberg, Dawn Kalous, Edward Abraham, Leonard D. Hudson, Neil R. MacIntyre, David C. Thompson, Kenneth Leeper, Gail Wenzlow, Steven Dahlberg, Carolyn Paradise, Thomas Jefferson, Janice D'Hulst, Mark Sebastian, Myron Waclawiw, William J. Sibbald, Ron Dechert, Roy G. Brower, Charles Watts, Paul N. Lanken, Michael A. Gryzner, John Komara, Carolyn H. Welsh, Scott S. Emerson, Joe G N Garcia, Francine Molay, Aimee Girod, Susan K. Pingleton, Douglas Hayden, Barbara Finkel, Pamela Randall, Henry J. Silverman, Galen B. Toews, Dorothy B. Gail, James Orme, Nancy Ringwood, Jason Kelley, Charles B. Lawton, Chris Stevens, Lee Mallatratt, B. Taylor Thompson, Alejandro C. Arroliga, Richard Kallet, Gordon R. Bernard, Marek Ancukiewicz, Herbert P. Wiedemann, Andrea L. Harabin, Brian Daniel, Terry Clemmer, Arthur S. Slutsky, John D. Lockrem, Ronald V. Maier, Michael Matthay, Robert Sladen, Carroll Wilcox, Alan H. Morris, Wanda Corral, Deborah Arnoldi, Arthur P. Wheeler, Libby Stone, Robin M Davis, Harry Anderson, Fran Piedalue, Polly E. Parsons, Carolyn Smith, C. William Hanson, Carol H. Bosken, V. A. Denver, Michael D. Shasby, James M. Boyett, Christine Walberg, Claudette Lee, Gordon Bernard, Robert C. McIntyre, William J. Fulkerson, Jonathan E. Gottlieb

Publikováno v: Critical care medicine. 30(1)

To determine whether the administration of lisofylline (1-[5R-hydroxyhexyl]-3,7-dimethylxanthine) would decrease mortality in patients with acute lung injury (ALI) or acute respiratory distress syndrome (ARDS).A prospective, randomized, double-blind,

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::135de9fb099818bb68866ee6a8800884
https://pubmed.ncbi.nlm.nih.gov/11902272